Maciej J. Zamek‐Gliszczynski
GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Drug Transport and Resistance Mechanisms, Pharmacological Effects and Toxicity Studies, Pharmacogenetics and Drug Metabolism, HIV/AIDS drug development and treatment, Diabetes Treatment and Management
Most-Cited Works
- → Membrane transporters in drug development(2010)3,297 cited
- → Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites(2006)247 cited
- → Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance(2018)226 cited
- → Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium(2018)197 cited
- → ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport-Mediated PK and DDIs in Humans(2013)194 cited
- → Membrane transporters in drug development and as determinants of precision medicine(2024)189 cited
- → Pharmacokinetics of 5 (and 6)-Carboxy-2′,7′-Dichlorofluorescein and Its Diacetate Promoiety in the Liver(2003)169 cited
- → Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models(2014)142 cited
- → Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design(2015)139 cited
- → The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects(2016)120 cited